32 articles for WJ Hoekstra
The following articles (labelled with PubMed ID or TBD) are for your review
PMID
Data
Article Title
Organization
Design and optimization of highly-selective fungal CYP51 inhibitors.
Viamet Pharmaceuticals
Highly-selective 4-(1,2,3-triazole)-based P450c17a 17,20-lyase inhibitors.
Viamet Pharmaceuticals
Co-crystal structure guided array synthesis of PPARgamma inverse agonists.
Glaxosmithkline
Array synthesis of progesterone receptor antagonists: 3-aryl-1,2-diazepines.
Glaxosmithkline
Potent nonpeptide vasopressin receptor antagonists based on oxazino- and thiazinobenzodiazepine templates.
Johnson & Johnson Pharmaceutical Research & Development
Thrombin receptor (PAR-1) antagonists. Heterocycle-based peptidomimetics of the SFLLR agonist motif.
R. W. Johnson Pharmaceutical Research Institute
Solid-phase parallel synthesis applied to lead optimization: Discovery of potent analogues of the GPIIb/IIIa antagonist RWJ-50042
TBA
Piperidine-containing beta-arylpropionic acids as potent antagonists of alphavbeta3/alphavbeta5 integrins.
Johnson & Johnson Pharmaceutical Research and Development
Aza-bicyclic amino acid sulfonamides as alpha(4)beta(1)/alpha(4)beta(7) integrin antagonists.
Johnson & Johnson Pharmaceutical Research & Development
Synthesis and biological evaluation of novel indoloazepine derivatives as non-peptide vasopressin V2 receptor antagonists.
Johnson & Johnson Pharmaceutical Research & Development
Bridged bicyclic vasopressin receptor antagonists with V(2)-selective or dual V(1a)/V(2) activity.
Johnson and Johnson Pharmaceutical Research and Development
1,2,4-triazolo[3,4-a]pyridine as a novel, constrained template for fibrinogen receptor (GPIIb/IIIa) antagonists.
The R. W. Johnson Pharmaceutical Research Institute
Discovery and optimization of a novel series of thrombin receptor (par-1) antagonists: potent, selective peptide mimetics based on indole and indazole templates.
The R. W. Johnson Pharmaceutical Research Institute
Potent, orally active GPIIb/IIIa antagonists containing a nipecotic acid subunit. Structure-activity studies leading to the discovery of RWJ-53308.
The R. W. Johnson Pharmaceutical Research Institute
Photoactivatable peptides based on BMS-197525: a potent antagonist of the human thrombin receptor (PAR-1).
University At Stony Brook
Development of Highly Selective Pyrimidine-Based Aldosterone Synthase (CYP11B2) Inhibitors.
Selenity Therapeutics
Design and evaluation of nonpeptide fibrinogen gamma-chain based GPIIb/IIIa antagonists.
R. W. Johnson Pharmaceutical Research Institute
Discovery of novel quinoline-based estrogen receptor ligands using peptide interaction profiling.
Glaxosmithkline Research & Development
Discovery of non-steroidal mifepristone mimetics: pyrazoline-based PR antagonists.
Glaxosmithkline
Design and optimization of highly-selective, broad spectrum fungal CYP51 inhibitors.
Viamet Pharmaceuticals
A novel small-molecule tumor necrosis factor a inhibitor attenuates inflammation in a hepatitis mouse model.
Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College
Simple Pseudo-dipeptides with a P2' Glutamate: A NOVEL INHIBITOR FAMILY OF MATRIX METALLOPROTEASES AND OTHER METZINCINS.
French Alternative Energies and Atomic Energy Commission
Functional properties of the high-affinity TRPV1 (VR1) vanilloid receptor antagonist (4-hydroxy-5-iodo-3-methoxyphenylacetate ester) iodo-resiniferatoxin.
Merck Sharp and Dohme Research Laboratories
Species orthologs of the alpha-2A adrenergic receptor: the pharmacological properties of the bovine and rat receptors differ from the human and porcine receptors.
University of Nebraska